Abstracts tagged "patient questionnaires and psoriatic arthritis"

Abstract Number: 1390 • 2018 ACR/ARHP Annual Meeting
Impact of Psoriatic Arthritis from the Patient’s Perspective in the Context of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire: An Online Global Survey
Laura C. Coates¹, Ana-Maria Orbai², Valderilio F Azevedo³, Joseph C Cappelleri⁴, Jade Moser⁵, Ralph Lippe⁶, Irwin Lim⁷, Lihi Eder⁸, Pascal Richette⁹, Meng-Yu Weng¹⁰, Rubén Queiro¹¹ and Lara Fallon¹², ¹University of Oxford, Oxford, United Kingdom, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Universidade Federal do Paraná, Curitiba, Brazil, ⁴Pfizer Inc, Groton, CT, ⁵The Harris Poll, Rochester, NY, ⁶Pfizer Pharma GmbH, Berlin, Germany, ⁷BJC Health, Sydney, Australia, ⁸Women’s College Research Institute, University of Toronto, Toronto, ON, Canada, ⁹Lariboisière Hospital, Lariboisière, University of Paris 7, Paris, France, ¹⁰Department of Internal Medicine, Division of Allergy, Immunology and Rheumatology, National Cheng Kung University Medical College and Hospital, Tainan, Taiwan, ¹¹Rheumatology Division, HUCA, Oviedo, Spain, ¹²Pfizer Canada, Montreal, QC, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a complex disease with high impact on quality of life (QoL). The PsA core domain set1 includes pain, patient (pt)…
Abstract Number: 2341 • 2018 ACR/ARHP Annual Meeting
A Link between Quality of Patient–Rheumatologist Communication and Patient Healthcare Needs in Psoriatic Arthritis: An Online Survey of US-Based Patients and Rheumatologists
Ana-Maria Orbai¹, Laura C. Coates², Valderilio F Azevedo³, Amit Garg⁴, Amar Majjhoo⁵, Christopher E M Griffiths⁶, Pamela Young⁷, Joseph C Cappelleri⁸, Jade Moser⁹ and Lara Fallon¹⁰, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²University of Oxford, Oxford, United Kingdom, ³Universidade Federal do Paraná, Curitiba, Brazil, ⁴Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, ⁵Shores Rheumatology, St Clair Shores, MI, ⁶Dermatology Centre, University of Manchester, Manchester, United Kingdom, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Groton, CT, ⁹The Harris Poll, Rochester, NY, ¹⁰Pfizer Canada, Montreal, QC, Canada
Background/Purpose: Patient (pt)–rheumatologist (rheum) communication may influence symptom reporting and disease control in psoriatic arthritis (PsA). This online survey evaluated pt–rheum communication and assessed PsA…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].